Mozobil Boosts Stem Cells Before Bone Marrow Transplants

FRIDAY, Dec. 19 (HealthDay News) -- The Genzyme Corp. drug Mozobil (plerixafor) has been approved by the U.S. Food and Drug Administration to boost a person's blood stem cell count before a bone marrow transplant, the agency said in a news release.

A bone marrow transplant is often performed in people with certain forms of cancer -- multiple myeloma and non-Hodgkin's lymphoma. Before getting high doses of chemotherapy or radiation, people with these forms of cancer may be advised to have blood stem cells collected so the cells can be re-infused after the therapy. Mozobil helps increase the number of stem cells before collection.

The most frequent side effects of Mozobil reported during clinical testing included diarrhea, nausea, fatigue, reactions near the injection site, headache, joint pain and dizziness.

More information

The U.S. Food and Drug Administration has more about this drug's approval history.

Join the Discussion
You are using an outdated version of Internet Explorer. Please click here to upgrade your browser in order to comment.
blog comments powered by Disqus
You Might Also Like...
See It, Share It
PHOTO: Oscar de la Renta and Oprah Winfrey attend the Costume Institute Gala Benefit to celebrate the opening of the American Woman: Fashioning a National Identity exhibition at The Metropolitan Museum of Art, May 8, 2010, in New York City.
Rabbani and Solimene Photography/WireImage/Getty Images
PHOTO: Up in Ash: Mount Sinabung Erupting
Tibt Nangin/Anadolu Agency/Getty Images
PHOTO: Firefighters rescue a woman who got stuck in a chimney in Thousand Oaks, Calif.
Ventura County Fire Department
PHOTO: Apple Pay is demonstrated at Apple headquarters on Oct. 16, 2014 in Cupertino, Calif.
Marcio Jose Sanchez/AP Photo